__timestamp | AstraZeneca PLC, AZN | Eli Lilly and Company, LLY | GSK plc, GSK | Takeda Pharmaceutical Company Limited, TAK |
---|---|---|---|---|
Sunday, January 1, 2023 | 0.131096018275 | 0.15835540985000002 | 0.165942505425 | 0.07769671430000001 |
Monday, January 1, 2024 | 0.16040004154999998 | 0.25915326390000004 | 0.1454220018 | 0.0326671886 |
Wednesday, January 1, 2025 | 0.0788483348 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis delves into the net income margins of four major players: GlaxoSmithKline (GSK), AstraZeneca (AZN), Takeda (TAK), and Eli Lilly (LLY) over the past two years.
It's important to note that some data points for 2025 are missing, which could affect the overall trend analysis. However, the available data provides a clear picture of the financial trajectories of these companies.
This comparative analysis offers valuable insights into the financial performance of these pharmaceutical giants, helping investors and stakeholders make informed decisions. Stay tuned for more updates as new data becomes available.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters